Form 4: Champions Oncology President Acquires Options to Purchase Common Stock

Brady Davis, President of Champions Oncology, Inc., reports the acquisition of options to purchase common stock in a recent SEC Form 4 filing.

Summary

• Brady Davis, President of Champions Oncology, Inc., filed a Form 4 with the SEC on April 1, 2024, reporting transactions related to derivative securities.
• On October 9, 2023, Davis acquired options to purchase 135,000 shares of common stock at an exercise price of $6.50.
• These options vest over a four-year period, starting October 9, 2024, and are exercisable over a ten-year period.
• Davis also acquired options to purchase 7,500 shares of common stock at $6.50, which vest fully on October 9, 2024, and are exercisable over a ten-year period.
• Additionally, Davis acquired options to purchase 68,000 shares of common stock at $6.50, vesting over four years from the achievement of specific performance criteria and exercisable over ten years.
• Following these transactions, Davis directly holds options to purchase a total of 210,500 shares of Champions Oncology common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of stock option grants, which is neither overtly positive nor negative.

Positives

• The acquisition of options by a company president can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

This filing is a routine disclosure related to executive compensation and stock ownership, common in the biotechnology and pharmaceutical industries.

Comparison to Industry Standards

• Option grants are a common form of executive compensation in the biotechnology industry, used to align management's interests with those of shareholders.
• The vesting schedules and exercise prices are typical for such grants, often tied to performance metrics and long-term value creation.

Stakeholder Impact

• The granting of stock options can align the interests of management with those of shareholders, potentially leading to increased company value.

Key Dates